autologous BCMA-targeted CAR T cells

Autologous BCMA-targeted CAR T cells represent a class of cellular immunotherapies engineered to target B-cell maturation antigen (BCMA), a protein highly and selectively expressed on the surface of malignant plasma cells in multiple myeloma. This therapeutic platform involves harvesting a patient's own T cells, genetically modifying them ex vivo (typically using a lentiviral or retroviral vector) to express a chimeric antigen receptor (CAR) specific for BCMA, expanding the cells, and reinfusing them back into the patient following lymphodepleting chemotherapy. Once reinfused, these CAR T cells recognize and bind to BCMA-expressing myeloma cells, leading to T-cell activation, proliferation, and targeted tumor cell lysis. Several specific therapies within this platform have been developed or approved, including idecabtagene vicleucel (Abecma), ciltacabtagene autoleucel (Carvykti), zevorcabtagene autoleucel (Fucaso/CT053), and equecabtagene autoleucel (CT103A).

Other names

BCMA CAR-T cellsBCMA-redirected autologous T cellsCAR-BCMA T cellsautologous BCMA-directed CAR T cellsautologous anti-BCMA CAR-T cells